Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 3/20 | 0.53 |
| ▸ | CTSH | P09668 | 1/20 | 0.53 |
| ▸ | CXCL8 | P10145 | 10/20 | 0.51 |
| ▸ | F2 | P00734 | 4/20 | 0.51 |
| ▸ | MC4R | P32245 | 2/20 | 0.49 |
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | MC5R | P33032 | 1/20 | 0.45 |
| ▸ | MC3R | P41968 | 1/20 | 0.45 |
| ▸ | MC1R | Q01726 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31050545 | 0.94 | MC4R (0.53) | CTSLCTSSCTSKCTSHCXCL8 | |
| SCHEMBL30910841 | 0.89 | CTSL (0.52) | CTSLCTSSCTSKCTSHCXCL8 | |
| SCHEMBL7200318 | 0.83 | CTSL (0.49) | CTSLCTSSCTSKCTSHF2 | |
| SCHEMBL7200319 | 0.83 | CTSL (0.49) | CTSLCTSSCTSKCTSHF2 | |
| SCHEMBL31437190 | 0.82 | CTSL (0.62) | CTSLCTSSCTSKCTSHCXCL8 | |
| SCHEMBL29506917 | 0.81 | CXCL8 (0.52) | CTSLCTSSCTSKCTSHCXCL8 | |
| SCHEMBL30567437 | 0.80 | OPRM1 (0.56) | CTSLCTSSCTSKCTSHCXCL8 | |
| SCHEMBL31437180 | 0.79 | CTSL (0.66) | CTSLCTSSCTSKCTSHCXCL8 | |
| SCHEMBL31437178 | 0.79 | CTSL (0.63) | CTSLCTSSCTSKCTSHCXCL8 | |
| SCHEMBL29972919 | 0.78 | F2 (0.55) | CTSLCTSSCTSKCTSHCXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269226-A1 | COMBINATION THERAPY WITH SEMAX AND CANNABIDIOL | HALLSTAT CAPITAL, LLC | 2024-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269226-A1 | COMBINATION THERAPY WITH SEMAX AND CANNABIDIOL | CNR2, CNR1, BAD | CTSL 2347/4885CTSS 3245/4885CTSK 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.